Strategic Partnerships
Advancing innovation together
A platform built for growth
SPORASTAT combines scientific innovation, regulatory efficiency, and commercially validated ingredients to create a compelling partnership opportunity.
Patented Innovation
Protected intellectual property centered on a novel multi-mechanism formulation.
Reduced Development Risk
Developed through the FDA's 505(b)(2) pathway using well-established active ingredients.
Clinically Proven Ingredients
Built on four FDA-established active ingredients with decades of clinical use.
Commercial Potential
Designed to address multiple skin and nail conditions within a large and growing therapeutic market.
Ways to collaborate
We're seeking strategic partners who share our vision for advancing innovative topical therapies.
Licensing
Commercial licensing opportunities.
Distribution
Regional or international commercialization.
Investment
Support the next stage of clinical and commercial development.
Strategic Alliances
Collaborate on research, manufacturing, or market expansion.
Positioned for efficient development
SPORASTAT's development strategy is designed to reduce technical and regulatory uncertainty while accelerating potential market entry.
Leverages existing safety and efficacy data.
Four active ingredients with extensive clinical history.
Potentially reducing development costs compared to a traditional NDA approach.
Patented formulation supporting long-term commercial differentiation.
A ready-to-develop asset
Expand your product portfolio with a patented, multi-action antifungal solution engineered to high-quality regulatory standards and ready for commercial distribution.
Patented & Protected (FTO)
Granted U.S. patent with fully confirmed Freedom to Operate, securing legal exclusivity and market protection.
Distribution-Ready Brand Identity
Complete visual identity and a robust clinical narrative fully prepared for seamless integration and immediate commercial launch.
Scalable Pipeline Opportunities
Designed to fill a vital gap in the prescription topical pipeline. Flexible milestone-based and royalty partnership structures available.
De-Risked FDA Pathway
Strategically engineered under the FDA 505(b)(2) regulatory pathway to minimize research risk and accelerate time-to-market.
High Unmet Clinical Need
Specifically formulated to address underserved polymicrobial infections, capturing a high-value, documented gap in the market.
Strong Commercial Pull
Proven market demand driven by multi-action clinical reliability, generating immediate pull from both clinicians and patients.
